Genetics and epigenetics of sporadic thyroid cancer

Molecular and Cellular Endocrinology

Volumn 386, Issue 1-2, 2014, Pages 55-66

  Vu Phan, Dang ^a   Koenig, Ronald J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Anaplastic; BRAF; Follicular; Papillary; PAX8 PPARG; RAS

Indexed keywords

B RAF KINASE; HYBRID PROTEIN; ISOCITRATE DEHYDROGENASE 1; PAX8 PPARG FUSION PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; PROTEIN RET; RAS PROTEIN; THYROID HORMONE RECEPTOR BETA; UNCLASSIFIED DRUG; UNTRANSLATED RNA;

BRAF GENE; CANCER GENETICS; CHROMOSOME TRANSLOCATION; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETICS; GENE; GENE FUSION; GENE MUTATION; GENETIC ASSOCIATION; HISTONE MODIFICATION; HUMAN; IDH1 GENE; NONHUMAN; NTRK1 GENE; ONCOGENE RAS; PAX8 PPARG GENE; PRIORITY JOURNAL; PTEN GENE; RET GENE; REVIEW; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; TUMOR SUPPRESSOR GENE;

ANAPLASTIC; BRAF; FOLLICULAR; PAPILLARY; PAX8-PPARG; RAS;

ANIMALS; EPIGENESIS, GENETIC; HUMANS; MICE; MUTATION; NEOPLASM PROTEINS; THYROID NEOPLASMS;

EID: 84896727459     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.07.030     Document Type: Review

References (228)

1. Adeniran A.J., Zhu Z., Gandhi M., Steward D.L., Fidler J.P., Giordano T.J., Biddinger P.W., Nikiforov Y.E. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am. J. Surg. Pathol. 2006, 30:216-222.
2. Aldred M.A., Morrison C., Gimm O., Hoang-Vu C., Krause U., Dralle H., Jhiang S., Eng C. Peroxisome proliferator-activated receptor gamma is frequently downregulated in a diversity of sporadic nonmedullary thyroid carcinomas. Oncogene 2003, 22:3412-3416.
3. Alipov G., Ito M., Prouglo Y., Takamura N., Yamashita S. Ret proto-oncogene rearrangement in thyroid cancer around Semipalatinsk nuclear testing site. Lancet 1999, 354:1528-1529.
4. Antico Arciuch V.G., Russo M.A., Dima M., Kang K.S., Dasrath F., Liao X.H., Refetoff S., Montagna C., Di Cristofano A. Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors. Oncotarget. 2011, 2:1109-1126.
5. Arlot-Bonnemains Y., Baldini E., Martin B., Delcros J.-G., Toller M., Curcio F., Ambesi-Impiombato F.S., D'Armiento M., Ulisse S. Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines. Endocr. Relat. Cancer 2008, 15:559-568.
6. Au A.Y.M., McBride C., Wilhelm K.G., Koenig R.J., Speller B., Cheung L., Messina M., Wentworth J., Tasevski V., Learoyd D., Robinson B.G., Clifton-Bligh R.J. PAX8-peroxisome proliferator-activated receptor γ (PPARγ) disrupts normal PAX8 or PPARγ transcriptional function and stimulates follicular thyroid cell growth. Endocrinology 2006, 147:367-376.
7. Avruch J., Khokhlatchev A., Kyriakis J.M., Luo Z., Tzivion G., Vavvas D., Zhang X.-F. Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade. Recent Prog. Horm. Res. 2001, 56:127-156.
8. Baitei E.Y., Zou M., Al-Mohanna F., Collison K., Alzahrani A.S., Farid N.R., Meyer B., Shi Y. Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma. J. Pathol. 2009, 217:707-715.
9. Baldini E., Sorrenti S., D'Armiento E., Guaitoli E., Morrone S., D'Andrea V., Gnessi L., Moretti C., Antonelli A., Catania A., De Antoni E., Ulisse S. Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines. Clin. Ter. 2012, 163:e307-313.
10. Baloch Z.W., LiVolsi V.A. Pathologic diagnosis of papillary thyroid carcinoma: today and tomorrow. Exp. Rev. Mol. Diagn. 2005, 5:573+.
11. Bamford S., Dawson E., Forbes S., Clements J., Pettett R., Dogan A., Flanagan A., Teague J., Futreal P.A., Stratton M.R., Wooster R. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br. J. Cancer 2004, 91:355-358.
12. Barollo S., Pennelli G., Vianello F., Watutantrige Fernando S., Negro I., Merante Boschin I., Pelizzo M.R., Rugge M., Mantero F., Nacamulli D., Girelli M.E., Busnardo B., Mian C. BRAF in primary and recurrent papillary thyroid cancers: the relationship with (131)I and 2-[(18)F]fluoro-2-deoxy-D-glucose uptake ability. Eur. J. Endocrinol. 2010, 163:659-663.
13. Basolo F., Pisaturo F., Pollina L.E., Fontanini G., Elisei R., Molinaro E., Iacconi P., Miccoli P., Pacini F. N-ras mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid 2000, 10:19-23.
14. Basolo F., Giannini R., Monaco C., Melillo R.M., Carlomagno F., Pancrazi M., Salvatore G., Chiappetta G., Pacini F., Elisei R., Miccoli P., Pinchera A., Fusco A., Santoro M. Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in Tall-Cell variant of papillary thyroid carcinoma. Am. J. Pathol. 2002, 160:247-254.
15. Biran A., Brownstein M., Haklai R., Kloog Y. Downregulation of survivin and aurora A by histone deacetylase and RAS inhibitors: a new drug combination for cancer therapy. Int. J. Cancer 2011, 128:691-701.
16. Bond J.A., Wyllie F.S., Rowson J., Radulescu A., Wynford-Thomas D. In vitro reconstruction of tumour initiation in a human epithelium. Oncogene 1994, 9:281-290.
17. Bongarzone I., Pierotti M.A., Monzini N., Mondellini P., Manenti G., Donghi R., Pilotti S., Grieco M., Santoro M., Fusco A. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma. Oncogene 1989, 4:1457-1462.
18. Bongarzone I., Butti M.G., Coronelli S., Borrello M.G., Santoro M., Mondellini P., Pilotti S., Fusco A., Della Porta G., Pierotti M.A. Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas. Cancer Res. 1994, 54:2979-2985.
19. Borbone E., Berlingieri M.T., De Bellis F., Nebbioso A., Chiappetta G., Mai A., Altucci L., Fusco A. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome-dependent inhibition of TRAIL degradation. Oncogene 2010, 29:105-116.
20. Bounacer A., Wicker R., Caillou B., Cailleux A.F., Sarasin A., Schlumberger M., Suárez H.G. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 1997, 15:1263-1273.
21. Bunone G., Uggeri M., Mondellini P., Pierotti M.A., Bongarzone I. RET receptor expression in thyroid follicular epithelial cell-derived tumors. Cancer Res. 2000, 60:2845-2849.
22. Cancer of the Thyroid - SEER Stat Fact Sheets [WWW Document], n.d. (accessed 10.4.12). http://www.seer.cancer.gov/statfacts/html/thyro.html.
23. Cantwell-Dorris E.R., O'Leary J.J., Sheils O.M. BRAFV600E: implications for carcinogenesis and molecular therapy. Mol. Cancer Ther. 2011, 10:385-394.
24. Capdevila J., Iglesias L., Halperin I., Segura A., Martínez-Trufero J., Vaz M.Á., Corral J., Obiols G., Grande E., Grau J.J., Tabernero J. Sorafenib in metastatic thyroid cancer. Endocr. Relat. Cancer 2012, 19:209-216.
25. Caronia L.M., Phay J.E., Shah M.H. Role of BRAF in thyroid oncogenesis. Clin. Cancer Res. 2011, 17:7511-7517.
26. Carr L.L., Mankoff D.A., Goulart B.H., Eaton K.D., Capell P.T., Kell E.M., Bauman J.E., Martins R.G. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin. Cancer Res. 2010, 16:5260-5268.
27. Catalano M.G., Fortunati N., Pugliese M., Poli R., Bosco O., Mastrocola R., Aragno M., Boccuzzi G. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J. Endocrinol. 2006, 191:465-472.
28. Catalano M.G., Pugliese M., Poli R., Bosco O., Bertieri R., Fortunati N., Boccuzzi G. Effects of the histone deacetylase inhibitor valproic acid on the sensitivity of anaplastic thyroid cancer cell lines to imatinib. Oncol. Rep. 2009, 21:515-521.
29. Catalano M.G., Pugliese M., Gargantini E., Grange C., Bussolati B., Asioli S., Bosco O., Poli R., Compagnone A., Bandino A., Mainini F., Fortunati N., Boccuzzi G. Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo. Int. J. Cancer 2012, 130:694-704.
30. Chan D., Tyner J.W., Chng W.J., Bi C., Okamoto R., Said J., Ngan B.D., Braunstein G.D., Koeffler H.P. Effect of dasatinib against thyroid cancer cell lines in vitro and a xenograft model in vivo. Oncol. Lett. 2012, 3:807-815.
31. Charles R.-P., Iezza G., Amendola E., Dankort D., McMahon M. Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse. Cancer Res. 2011, 71:3863-3871.
32. Chi P., Allis C.D., Wang G.G. Covalent histone modifications-miswritten, misinterpreted and mis-erased in human cancers. Nat. Rev. Cancer 2010, 10:457-469.
33. Ciampi R., Knauf J.A., Kerler R., Gandhi M., Zhu Z., Nikiforova M.N., Rabes H.M., Fagin J.A., Nikiforov Y.E. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J. Clin. Invest. 2005, 115:94-101.
34. Cohen Y., Xing M., Mambo E., Guo Z., Wu G., Trink B., Beller U., Westra W.H., Ladenson P.W., Sidransky D. BRAF mutation in papillary thyroid carcinoma. J. Natl. Cancer Inst. 2003, 95:625-627.
35. Collins B.J., Chiappetta G., Schneider A.B., Santoro M., Pentimalli F., Fogelfeld L., Gierlowski T., Shore-Freedman E., Jaffe G., Fusco A. RET expression in papillary thyroid cancer from patients irradiated in childhood for benign conditions. J. Clin. Endocrinol. Metab. 2002, 87:3941-3946.
36. Cooper D.S., Doherty G.M., Haugen B.R., Kloos R.T., Lee S.L., Mandel S.J., Mazzaferri E.L., McIver B., Pacini F., Schlumberger M., Sherman S.I., Steward D.L., Tuttle R.M. Revised american thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19:1167-1214.
37. Croyle M., Akeno N., Knauf J.A., Fabbro D., Chen X., Baumgartner J.E., Lane H.A., Fagin J.A. RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res. 2008, 68:4183-4191.
38. Dahia P.L., Marsh D.J., Zheng Z., Zedenius J., Komminoth P., Frisk T., Wallin G., Parsons R., Longy M., Larsson C., Eng C. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 1997, 57:4710-4713.
39. Diallo-Krou E., Yu J., Colby L.A., Inoki K., Wilkinson J.E., Thomas D.G., Giordano T.J., Koenig R.J. Paired box gene 8-peroxisome proliferator-activated receptor-γ fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice. Endocrinology 2009, 150:5181-5190.
40. Dobson M.E., Diallo-Krou E., Grachtchouk V., Yu J., Colby L.A., Wilkinson J.E., Giordano T.J., Koenig R.J. Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARγ fusion protein thyroid carcinoma. Endocrinology 2011, 152:4455-4465.
41. Dom G., Galdo V.C., Tarabichi M., Tomás G., Hébrant A., Andry G., De Martelar V., Libert F., Leteurtre E., Dumont J.E., Maenhaut C., van Staveren W.C.G. 5-aza-2'-deoxycytidine has minor effects on differentiation in human thyroid cancer cell lines, but modulates genes that are involved in adaptation in vitro. Thyroid 2013, 23:317-328.
42. Donghi R., Longoni A., Pilotti S., Michieli P., Della Porta G., Pierotti M.A. Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. J. Clin. Invest. 1993, 91:1753-1760.
43. Durante C., Puxeddu E., Ferretti E., Morisi R., Moretti S., Bruno R., Barbi F., Avenia N., Scipioni A., Verrienti A., Tosi E., Cavaliere A., Gulino A., Filetti S., Russo D. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J. Clin. Endocrinol. Metab. 2007, 92:2840-2843.
44. Eberhardt N.L., Grebe S.K.G., McIver B., Reddi H.V. The role of the PAX8/PPARγ fusion oncogene in the pathogenesis of follicular thyroid cancer. Mol. Cell Endocrinol. 2010, 321:50-56.
45. Elisei R., Shiohara M., Koeffler H.P., Fagin J.A. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas. Cancer 1998, 83:2185-2193.
46. Elisei R., Viola D., Torregrossa L., Giannini R., Romei C., Ugolini C., Molinaro E., Agate L., Biagini A., Lupi C., Valerio L., Materazzi G., Miccoli P., Piaggi P., Pinchera A., Vitti P., Basolo F. The BRAFV600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J. Clin. Endocrinol. Metab. 2012, 97:4390-4398.
47. Espadinha C., Cavaco B.M., Leite V. PAX8PPARgamma stimulates cell viability and modulates expression of thyroid-specific genes in a human thyroid cell line. Thyroid 2007, 17:497-509.
48. Fagin J.A., Matsuo K., Karmakar A., Chen D.L., Tang S.H., Koeffler H.P. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J. Clin. Invest. 1993, 91:179-184.
49. Fan M., Li X., Jiang W., Huang Y., Li J., Wang Z. A long non-coding RNA, PTCSC3, as a tumor suppressor and a target of miRNAs in thyroid cancer cells. Exp. Ther. Med. 2013, 5:1143-1146.
50. Fard-Esfahani P., Fard-Esfahani A., Saidi P., Fayaz S., Mohabati R., Majdi M. An increased risk of differentiated thyroid carcinoma in Iran with the 677C→T homozygous polymorphism in the MTHFR Gene. Cancer Epidemiol. 2011, 35:56-58.
51. Fernandez I.J., Piccin O., Sciascia S., Cavicchi O., Repaci A., Vicennati V., Fiorentino M. Clinical significance of BRAF mutation in thyroid papillary cancer. Otolaryngol. Head Neck Surg. 2013, 148:919-925.
52. Frattini M., Ferrario C., Bressan P., Balestra D., De Cecco L., Mondellini P., Bongarzone I., Collini P., Gariboldi M., Pilotti S., Pierotti M.A., Greco A. Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer. Oncogene 2004, 23:7436-7440.
53. French C.A., Alexander E.K., Cibas E.S., Nose V., Laguette J., Faquin W., Garber J., Moore F., Fletcher J.A., Larsen P.R., Kroll T.G. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am. J. Pathol. 2003, 162:1053-1060.
54. Fugazzola L., Pilotti S., Pinchera A., Vorontsova T.V., Mondellini P., Bongarzone I., Greco A., Astakhova L., Butti M.G., Demidchik E.P. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res. 1995, 55:5617-5620.
55. Furuya F., Shimura H., Suzuki H., Taki K., Ohta K., Haraguchi K., Onaya T., Endo T., Kobayashi T. Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 2004, 145:2865-2875.
56. Furuya F., Hanover J.A., Cheng S. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. Proc. Natl. Acad. Sci. USA 2006, 103:1780-1785.
57. Furuya F., Lu C., Willingham M.C., Cheng S.-Y. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 2007, 28:2451-2458.
58. Gandhi M., Dillon L.W., Pramanik S., Nikiforov Y.E., Wang Y.-H. DNA breaks at fragile sites generate oncogenic RET/PTC rearrangements in human thyroid cells. Oncogene 2010, 29:2272-2280.
59. Gandhi M., Evdokimova V., Nikiforov Y.E. Mechanisms of chromosomal rearrangements in solid tumors: the model of papillary thyroid carcinoma. Mol. Cell Endocrinol. 2010, 321:36-43.
60. Gandhi M., Evdokimova V., Nikiforov Y.E. Frequency of close positioning of chromosomal loci detected by FRET correlates with their participation in carcinogenic rearrangements in human cells. Genes Chromosomes Cancer 2012, 51:1037-1044.
61. Gao W.L., Wie L.L., Chao Y.G., Wie L., Song T.L. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas. Clin. Lab. 2012, 58:919-926.
62. Garcia-Rostan G., Zhao H., Camp R.L., Pollan M., Herrero A., Pardo J., Wu R., Carcangiu M.L., Costa J., Tallini G. Ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J. Clin. Oncol. 2003, 21:3226-3235.
63. Giordano T.J., Au A.Y.M., Kuick R., Thomas D.G., Rhodes D.R., Wilhelm K.G., Vinco M., Misek D.E., Sanders D., Zhu Z., Ciampi R., Hanash S., Chinnaiyan A., Clifton-Bligh R.J., Robinson B.G., Nikiforov Y.E., Koenig R.J. Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation. Clin. Cancer Res. 2006, 12:1983-1993.
64. Goyette P., Sumner J.S., Milos R., Duncan A.M., Rosenblatt D.S., Matthews R.G., Rozen R. Human methylenetetrahydrofolate reductase: isolation of cDNA, mapping and mutation identification. Nat. Genet. 1994, 7:195-200.
65. Greco A., Mariani C., Miranda C., Lupas A., Pagliardini S., Pomati M., Pierotti M.A. The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain. Mol. Cell. Biol. 1995, 15:6118-6127.
66. Grieco M., Santoro M., Berlingieri M.T., Melillo R.M., Donghi R., Bongarzone I., Pierotti M.A., Della Porta G., Fusco A., Vecchio G. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990, 60:557-563.
67. Guerra A., Sapio M.R., Marotta V., Campanile E., Rossi S., Forno I., Fugazzola L., Budillon A., Moccia T., Fenzi G., Vitale M. The primary occurrence of BRAFV600E is a rare clonal event in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 2012, 97:517-524.
68. Guigon C.J., Cheng S. Novel nongenomic signaling of thyroid hormone receptors in thyroid carcinogenesis. Mol. Cell. Endocrinol. 2009, 308:63-69.
69. Guigon C.J., Zhao L., Lu C., Willingham M.C., Cheng S. Regulation of β-catenin by a novel nongenomic action of thyroid hormone β receptor. Mol. Cell. Biol. 2008, 28:4598-4608.
70. Guigon C.J., Zhao L., Willingham M.C., Cheng S.-Y. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer. Oncogene 2009, 28:509-517.
71. Gupta R.A., Shah N., Wang K.C., Kim J., Horlings H.M., Wong D.J., Tsai M.-C., Hung T., Argani P., Rinn J.L., Wang Y., Brzoska P., Kong B., Li R., West R.B., van de Vijver M.J., Sukumar S., Chang H.Y. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464:1071-1076.
72. Gupta N., Dasyam A.K., Carty S.E., Nikiforova M.N., Ohori N.P., Armstrong M., Yip L., Lebeau S.O., McCoy K.L., Coyne C., Stang M.T., Johnson J., Ferris R.L., Seethala R., Nikiforov Y.E., Hodak S.P. RAS mutations in thyroid fna specimens are highly predictive of predominantly low-risk follicular-pattern cancers. J. Clin. Endocrinol. Metab. 2013, 98:E914-922.
73. Gupta-Abramson V., Troxel A.B., Nellore A., Puttaswamy K., Redlinger M., Ransone K., Mandel S.J., Flaherty K.T., Loevner L.A., O'Dwyer P.J., Brose M.S. Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol. 2008, 26:4714-4719.
74. Halachmi N., Halachmi S., Evron E., Cairns P., Okami K., Saji M., Westra W.H., Zeiger M.A., Jen J., Sidransky D. Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors. Genes Chromosomes Cancer 1998, 23:239-243.
75. Hansen K.D., Timp W., Bravo H.C., Sabunciyan S., Langmead B., McDonald O.G., Wen B., Wu H., Liu Y., Diep D., Briem E., Zhang K., Irizarry R.A., Feinberg A.P. Increased methylation variation in epigenetic domains across cancer types. Nat. Genet. 2011, 43:768-775.
76. Hara H., Fulton N., Yashiro T., Ito K., DeGroot L.J., Kaplan E.L. N-ras mutation: an independent prognostic factor for aggressiveness of papillary thyroid carcinoma. Surgery 1994, 116:1010-1016.
77. Hemerly J.P., Bastos A.U., Cerutti J.M. Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas. Eur. J. Endocrinol. 2010, 163:747-755.
78. Ho A.L., Grewal R.K., Leboeuf R., Sherman E.J., Pfister D.G., Deandreis D., Pentlow K.S., Zanzonico P.B., Haque S., Gavane S., Ghossein R.A., Ricarte-Filho J.C., Domínguez J.M., Shen R., Tuttle R.M., Larson S.M., Fagin J.A. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N. Engl. J. Med. 2013, 368:623-632.
79. Hoftijzer H., Heemstra K.A., Morreau H., Stokkel M.P., Corssmit E.P., Gelderblom H., Weijers K., Pereira A.M., Huijberts M., Kapiteijn E., Romijn J.A., Smit J.W. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 2009, 161:923-931.
80. Hong D.S., Cabanillas M.E., Wheler J., Naing A., Tsimberidou A.M., Ye L., Waguespack S.G., Hernandez M., Naggar A.K.E., Bidyasar S., Wright J., Sherman S.I., Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J. Clin. Endocrinol. Metab. 2011, 96:997-1005.
81. Hou P., Liu D., Shan Y., Hu S., Studeman K., Condouris S., Wang Y., Trink A., El-Naggar A.K., Tallini G., Vasko V., Xing M. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin. Cancer Res. 2007, 13:1161-1170.
82. Hou P., Ji M., Xing M. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer 2008, 113:2440-2447.
83. Howitt B.E., Jia Y., Sholl L.M., Barletta J. Molecular alterations in partially-encapsulated/well-circumscribed follicular variant of papillary thyroid carcinoma. Thyroid 2013, (Epub ahead of print).
84. Ito T., Seyama T., Iwamoto K.S., Hayashi T., Mizuno T., Tsuyama N., Dohi K., Nakamura N., Akiyama M. In vitro irradiation is able to cause RET oncogene rearrangement. Cancer Res. 1993, 53:2940-2943.
85. Jendrzejewski J., He H., Radomska H.S., Li W., Tomsic J., Liyanarachchi S., Davuluri R.V., Nagy R., de la Chapelle A. The polymorphism rs944289 predisposes to papillary thyroid carcinoma through a large intergenic noncoding RNA gene of tumor suppressor type. Proc. Natl. Acad. Sci. USA 2012, 109:8646-8651.
86. Jhiang S.M., Sagartz J.E., Tong Q., Parker-Thornburg J., Capen C.C., Cho J.Y., Xing S., Ledent C. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 1996, 137:375-378.
87. Jin N., Jiang T., Rosen D.M., Nelkin B.D., Ball D.W. Synergistic action of a RAF inhibitor and a dual PI3K/mTOR inhibitor in thyroid cancer. Clin. Cancer Res. 2011, 17:6482-6489.
88. Jo Y.S., Li S., Song J.H., Kwon K.H., Lee J.C., Rha S.Y., Lee H.J., Sul J.Y., Kweon G.R., Ro H.-K., Kim J.-M., Shong M. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2006, 91:3667-3670.
89. Kaneshige M., Kaneshige K., Zhu X., Dace A., Garrett L., Carter T.A., Kazlauskaite R., Pankratz D.G., Wynshaw-Boris A., Refetoff S., Weintraub B., Willingham M.C., Barlow C., Cheng S. Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. Proc. Natl. Acad. Sci. USA 2000, 97:13209-13214.
90. Kaplan D.R., Hempstead B.L., Martin-Zanca D., Chao M.V., Parada L.F. The trk proto-oncogene product: a signal transducing receptor for nerve growth factor. Science 1991, 252:554-558.
91. Karga H., Lee J.K., Vickery A.L., Thor A., Gaz R.D., Jameson J.L. Ras oncogene mutations in benign and malignant thyroid neoplasms. J. Clin. Endocrinol. Metab. 1991, 73:832-836.
92. Kato Y., Ying H., Willingham M.C., Cheng S.-Y. A tumor suppressor role for thyroid hormone β receptor in a mouse model of thyroid carcinogenesis. Endocrinology 2004, 145:4430-4438.
93. Kato Y., Ying H., Zhao L., Furuya F., Araki O., Willingham M.C., Cheng S.-Y. PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway. Oncogene 2006, 25:2736-2747.
94. Kim C.S., Vasko V.V., Kato Y., Kruhlak M., Saji M., Cheng S.-Y., Ringel M.D. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. Endocrinology 2005, 146:4456-4463.
95. Kim S., Yazici Y.D., Calzada G., Wang Z.-Y., Younes M.N., Jasser S.A., El-Naggar A.K., Myers J.N. Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Mol. Cancer Ther. 2007, 6:1785-1792.
96. Kim T.H., Park Y.J., Lim J.A., Ahn H.Y., Lee E.K., Lee Y.J., Kim K.W., Hahn S.K., Youn Y.K., Kim K.H., Cho B.Y., Park D.J. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012, 118:1764-1773.
97. Kim K., Cabanillas M., Lazar A.J., Williams M.D., Sanders D.L., Ilagan J.L., Nolop K., Lee R.J., Sherman S.I. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring v600ebraf mutation. Thyroid 2013, (Epub ahead of print).
98. Kim K., Jutooru I., Chadalapaka G., Johnson G., Frank J., Burghardt R., Kim S., Safe S. HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer. Oncogene 2013, 32:1616-1625.
99. Kim W.G., Zhu X., Kim D.W., Zhang L., Kebebew E., Cheng S.-Y. Reactivation of the silenced thyroid hormone receptor β gene expression delays thyroid tumor progression. Endocrinology 2013, 154:25-35.
100. Kitazono M., Robey R., Zhan Z., Sarlis N.J., Skarulis M.C., Aikou T., Bates S., Fojo T. Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J. Clin. Endocrinol. Metab. 2001, 86:3430-3435.
101. Kloos R.T., Ringel M.D., Knopp M.V., Hall N.C., King M., Stevens R., Liang J., Wakely P.E., Vasko V.V., Saji M., Rittenberry J., Wei L., Arbogast D., Collamore M., Wright J.J., Grever M., Shah M.H. Phase II trial of sorafenib in metastatic thyroid cancer. J. Clin. Oncol. 2009, 27:1675-1684.
102. Knauf J.A., Ma X., Smith E.P., Zhang L., Mitsutake N., Liao X.-H., Refetoff S., Nikiforov Y.E., Fagin J.A. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005, 65:4238-4245.
103. Knauf J.A., Ouyang B., Knudsen E.S., Fukasawa K., Babcock G., Fagin J.A. Oncogenic RAS induces accelerated transition through G2/M and promotes defects in the G2 DNA damage and mitotic spindle checkpoints. J. Biol. Chem. 2006, 281:3800-3809.
104. Kogo R., Shimamura T., Mimori K., Kawahara K., Imoto S., Sudo T., Tanaka F., Shibata K., Suzuki A., Komune S., Miyano S., Mori M. Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers. Cancer Res. 2011, 71:6320-6326.
105. Kondo T., Nakazawa T., Ma D., Niu D., Mochizuki K., Kawasaki T., Nakamura N., Yamane T., Kobayashi M., Katoh R. Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab. Invest. 2009, 89:791-799.
106. Kroll T.G., Sarraf P., Pecciarini L., Chen C.-J., Mueller E., Spiegelman B.M., Fletcher J.A. PAX8-PPARγ1 fusion in oncogene human thyroid carcinoma. Science 2000, 289:1357-1360.
107. La Perle K.M., Jhiang S.M., Capen C.C. Loss of p53 promotes anaplasia and local invasion in ret/PTC1-induced thyroid carcinomas. Am. J. Pathol. 2000, 157:671-677.
108. Lacroix L., Lazar V., Michiels S., Ripoche H., Dessen P., Talbot M., Caillou B., Levillain J.-P., Schlumberger M., Bidart J.-M. Follicular thyroid tumors with the PAX8-PPARγ1 rearrangement display characteristic genetic alterations. Am. J. Pathol. 2005, 167:223-231.
109. Lang F.F., Bruner J.M., Fuller G.N., Aldape K., Prados M.D., Chang S., Berger M.S., McDermott M.W., Kunwar S.M., Junck L.R., Chandler W., Zwiebel J.A., Kaplan R.S., Yung W.K.A. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J. Clin. Oncol. 2003, 21:2508-2518.
110. Lee J.T. Epigenetic regulation by long noncoding RNAs. Science 2012, 338:1435-1439.
111. Lemoine N.R., Mayall E.S., Wyllie F.S., Farr C.J., Hughes D., Padua R.A., Thurston V., Williams E.D., Wynford-Thomas D. Activated ras oncogenes in human thyroid cancers. Cancer Res. 1988, 48:4459-4463.
112. Levy R., Grafi-Cohen M., Kraiem Z., Kloog Y. Galectin-3 promotes chronic activation of K-Ras and differentiation block in malignant thyroid carcinomas. Mol. Cancer Ther. 2010, 9:2208-2219.
113. Li E., Beard C., Jaenisch R. Role for DNA methylation in genomic imprinting. Nature 1993, 366:362-365.
114. Li D., Feng J., Wu T., Wang Y., Sun Y., Ren J., Liu M. Long intergenic noncoding RNA HOTAIR is overexpressed and regulates PTEN methylation in laryngeal squamous cell carcinoma. Am. J. Pathol. 2013, 182:64-70.
115. Libertini S., Abagnale A., Passaro C., Botta G., Barbato S., Chieffi P., Portella G. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947. Endocr. Relat. Cancer 2011, 18:129-141.
116. Lim J.Y., Hong S.W., Lee Y.S., Kim B.-W., Park C.S., Chang H.-S., Cho J.Y. Clinicopathologic implications of the BRAFV600E mutation in papillary thyroid cancer; a subgroup analysis of 3130 cases in a single center. Thyroid 2013, (Epub ahead of print).
117. Lima J., Trovisco V., Soares P., Máximo V., Magalhães J., Salvatore G., Santoro M., Bogdanova T., Tronko M., Abrosimov A., Jeremiah S., Thomas G., Williams D., Sobrinho-Simões M. BRAF mutations are not a major event in post-chernobyl childhood thyroid carcinomas. J. Clin. Endocrinol. Metab. 2004, 89:4267-4271.
118. Lin S.-F., Huang Y.-Y., Lin J.-D., Chou T.-C., Hsueh C., Wong R.J. Utility of a PI3K/mTOR Inhibitor (NVP-BEZ235) for thyroid cancer therapy. PLoS ONE 2012, 7:e46726.
119. Liu D., Hu S., Hou P., Jiang D., Condouris S., Xing M. Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin. Cancer Res. 2007, 13:1341-1349.
120. Liu D., Liu Z., Condouris S., Xing M. BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J. Clin. Endocrinol. Metab. 2007, 92:2264-2271.
121. Liu Z., Hou P., Ji M., Guan H., Studeman K., Jensen K., Vasko V., El-Naggar A.K., Xing M. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J. Clin. Endocrinol. Metab. 2008, 93:3106-3116.
122. Liu R., Liu D., Trink E., Bojdani E., Ning G., Xing M. The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J. Clin. Endocrinol. Metab. 2011, 96:E577-585.
123. Liu R., Liu D., Xing M. The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. J. Clin. Endocrinol. Metab. 2012, 97:E173-182.
124. Losman J.A., Kaelin W.G. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013, 27:836-852.
125. Lui W.-O., Zeng L., Rehrmann V., Deshpande S., Tretiakova M., Kaplan E.L., Leibiger I., Leibiger B., Enberg U., Höög A., Larsson C., Kroll T.G. CREB3L2-PPARγ fusion mutation identifies a thyroid signaling pathway regulated by intramembrane proteolysis. Cancer Res. 2008, 68:7156-7164.
126. Lyons J.F., Wilhelm S., Hibner B., Bollag G. Discovery of a novel Raf kinase inhibitor. Endocr. Relat. Cancer 2001, 8:219-225.
127. Mandal M., Kim S., Younes M.N., Jasser S.A., El-Naggar A.K., Mills G.B., Myers J.N. The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells. Br. J. Cancer 2005, 92:1899-1905.
128. Manenti G., Pilotti S., Re F.C., Della Porta G., Pierotti M.A. Selective activation of ras oncogenes in follicular and undifferentiated thyroid carcinomas. Eur. J. Cancer 1994, 30A:987-993.
129. Marciano D., Ben-Baruch G., Marom M., Egozi Y., Haklai R., Kloog Y. Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth. J. Med. Chem. 1995, 38:1267-1272.
130. Marotta V., Guerra A., Sapio M.R., Vitale M. RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint. Eur. J. Endocrinol. 2011, 165:499-507.
131. Marotta V., Ramundo V., Camera L., Prete M.D., Fonti R., Esposito R., Palmieri G., Salvatore M., Vitale M., Colao A., Faggiano A. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clin. Endocrinol. (Oxf.) 2013, 78:760-767.
132. Marques A.R., Espadinha C., Frias M.J., Roque L., Catarino A.L., Sobrinho L.G., Leite V. Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours. Br. J. Cancer 2004, 91:732-738.
133. Matias-Guiu X., Cuatrecasas M., Musulen E., Prat J. P53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas. J. Clin. Pathol. 1994, 47:337-339.
134. Melillo R.M., Castellone M.D., Guarino V., De Falco V., Cirafici A.M., Salvatore G., Caiazzo F., Basolo F., Giannini R., Kruhoffer M., Orntoft T., Fusco A., Santoro M. The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J. Clin. Invest. 2005, 115:1068-1081.
135. Miozzo M., Pierotti M.A., Sozzi G., Radice P., Bongarzone I., Spurr N.K., Della Porta G. Human TRK proto-oncogene maps to chromosome 1q32-q41. Oncogene 1990, 5:1411-1414.
136. Mitsutake N., Knauf J.A., Mitsutake S., Mesa C., Zhang L., Fagin J.A. Conditional BRAFV600E expression induces DNA synthesis, apoptosis, dedifferentiation, and chromosomal instability in thyroid PCCL3 cells. Cancer Res. 2005, 65:2465-2473.
137. Miyagi E., Braga-Basaria M., Hardy E., Vasko V., Burman K.D., Jhiang S., Saji M., Ringel M.D. Chronic expression of RET/PTC 3 enhances basal and insulin-stimulated PI3 kinase/AKT signaling and increases IRS-2 expression in FRTL-5 thyroid cells. Mol. Carcinog. 2004, 41:98-107.
138. Mizuno T., Kyoizumi S., Suzuki T., Iwamoto K.S., Seyama T. Continued expression of a tissue specific activated oncogene in the early steps of radiation-induced human thyroid carcinogenesis. Oncogene 1997, 15:1455-1460.
139. Mizuno T., Iwamoto K.S., Kyoizumi S., Nagamura H., Shinohara T., Koyama K., Seyama T., Hamatani K. Preferential induction of RET/PTC1 rearrangement by X-ray irradiation. Oncogene 2000, 19:438-443.
140. Moretti S., Macchiarulo A., De Falco V., Avenia N., Barbi F., Carta C., Cavaliere A., Melillo R.M., Passeri L., Santeusanio F., Tartaglia M., Santoro M., Puxeddu E. Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma. Oncogene 2006, 25:4235-4240.
141. Murphy D.A., Makonnen S., Lassoued W., Feldman M.D., Carter C., Lee W.M.F. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006). Am. J. Pathol. 2006, 169:1875-1885.
142. Murugan A.K., Bojdani E., Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem. Biophys. Res. Commun. 2010, 393:555-559.
143. Musholt T.J., Musholt P.B., Khaladj N., Schulz D., Scheumann G.F., Klempnauer J. Prognostic significance of RET and NTRK1 rearrangements in sporadic papillary thyroid carcinoma. Surgery 2000, 128:984-993.
144. Nagaiah G., Hossain A., Mooney C.J., Parmentier J., Remick S.C. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment. J. Oncol. 2011, 2011:542358.
145. Nakamura T., Yana I., Kobayashi T., Shin E., Karakawa K., Fujita S., Miya A., Mori T., Nishisho I., Takai S. P53 gene mutations associated with anaplastic transformation of human thyroid carcinomas. Jpn. J. Cancer Res. 1992, 83:1293-1298.
146. Nakashima M., Takamura N., Namba H., Saenko V., Meirmanov S., Matsumoto N., Hayashi T., Maeda S., Sekine I. RET oncogene amplification in thyroid cancer: correlations with radiation-associated and high-grade malignancy. Hum. Pathol. 2007, 38:621-628.
147. Namba H., Rubin S.A., Fagin J.A. Point mutations of ras oncogenes are an early event in thyroid tumorigenesis. Mol. Endocrinol. 1990, 4:1474-1479.
148. Namba H., Nakashima M., Hayashi T., Hayashida N., Maeda S., Rogounovitch T.I., Ohtsuru A., Saenko V.A., Kanematsu T., Yamashita S. Clinical implication of Hot Spot BRAF mutation, V599E, in papillary thyroid cancers. J. Clin. Endocrinol. Metab. 2003, 88:4393-4397.
149. Nehs M.A., Nucera C., Nagarkatti S.S., Sadow P.M., Morales-Garcia D., Hodin R.A., Parangi S. Late intervention with anti-BRAF(V600E) therapy induces tumor regression in an orthotopic mouse model of human anaplastic thyroid cancer. Endocrinology 2012, 153:985-994.
150. Niinuma T., Suzuki H., Nojima M., Nosho K., Yamamoto H., Takamaru H., Yamamoto E., Maruyama R., Nobuoka T., Miyazaki Y., Nishida T., Bamba T., Kanda T., Ajioka Y., Taguchi T., Okahara S., Takahashi H., Nishida Y., Hosokawa M., Hasegawa T., Tokino T., Hirata K., Imai K., Toyota M., Shinomura Y. Upregulation of miR-196a and HOTAIR drive malignant character in gastrointestinal stromal tumors. Cancer Res. 2012, 72:1126-1136.
151. Nikiforov Y.E. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endocr. Pathol. 2004, 15:319-327.
152. Nikiforov Y.E. Molecular analysis of thyroid tumors. Mod. Pathol. 2011, 24:S34-S43.
153. Nikiforov Y.E., Rowland J.M., Bove K.E., Monforte-Munoz H., Fagin J.A. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997, 57:1690-1694.
154. Nikiforova M.N., Stringer J.R., Blough R., Medvedovic M., Fagin J.A., Nikiforov Y.E. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science 2000, 290:138-141.
155. Nikiforova M.N., Kimura E.T., Gandhi M., Biddinger P.W., Knauf J.A., Basolo F., Zhu Z., Giannini R., Salvatore G., Fusco A., Santoro M., Fagin J.A., Nikiforov Y.E. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 2003, 88:5399-5404.
156. Nikiforova M.N., Lynch R.A., Biddinger P.W., Alexander E.K., Dorn G.W., Tallini G., Kroll T.G., Nikiforov Y.E. RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J. Clin. Endocrinol. Metab. 2003, 88:2318-2326.
157. Noguchi H., Yamashita H., Murakami T., Hirai K., Noguchi Y., Maruta J., Yokoi T., Noguchi S. Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr. J. 2009, 56:245-249.
158. Nucera C., Goldfarb M., Hodin R., Parangi S. Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochim. Biophys. Acta 2009, 1795:152-161.
159. Orloff M.S., He X., Peterson C., Chen F., Chen J.-L., Mester J.L., Eng C. Germline PIK3CA and AKT1 mutations in Cowden and Cowden-like syndromes. Am. J. Hum. Genet. 2013, 92:76-80.
160. Ozdemir S., Silan F., Hasbek Z., Uludag A., Atik S., Erselcan T., Ozdemir O. Increased T-allele frequency of 677 C>T polymorphism in the methylenetetrahydrofolate reductase gene in differentiated thyroid carcinoma. Genet Test Mol. Biomarkers 2012, 16:780-784.
161. Paes J.E., Ringel M.D. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. Endocrinol. Metab. Clin. North Am. 2008, 37:375-387.
162. Pakneshan S., Salajegheh A., Smith R.A., Lam A.K.-Y. Clinicopathological relevance of BRAF mutations in human cancer. Pathology 2013, 45:346-356.
163. Papewalis C., Wuttke M., Schinner S., Willenberg H.S., Baran A.M., Scherbaum W.A., Schott M. Role of the novel mTOR inhibitor RAD001 (everolimus) in anaplastic thyroid cancer. Horm. Metab. Res. 2009, 41:752-756.
164. Park J.-W., Zarnegar R., Kanauchi H., Wong M.G., Hyun W.C., Ginzinger D.G., Lobo M., Cotter P., Duh Q.-Y., Clark O.H. Troglitazone, the peroxisome proliferator-activated receptor-γ agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines. Thyroid 2005, 15:222-231.
165. Paz M.F., Avila S., Fraga M.F., Pollan M., Capella G., Peinado M.A., Sanchez-Cespedes M., Herman J.G., Esteller M. Germ-line variants in methyl-group metabolism genes and susceptibility to DNA methylation in normal tissues and human primary tumors. Cancer Res. 2002, 62:4519-4524.
166. Powell D.J., Russell J., Nibu K., Li G., Rhee E., Liao M., Goldstein M., Keane W.M., Santoro M., Fusco A., Rothstein J.L. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. Cancer Res. 1998, 58:5523-5528.
167. Powell J.G., Wang X., Allard B.L., Sahin M., Wang X.-L., Hay I.D., Hiddinga H.J., Deshpande S.S., Kroll T.G., Grebe S.K., Eberhardt N.L., McIver B. The PAX8/PPARγ fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARγ inhibition. Oncogene 2004, 23:3634-3641.
168. Prasad V.V.T.S., Wilkhoo H. Association of the functional polymorphism C677T in the methylenetetrahydrofolate reductase gene with colorectal, thyroid, breast, ovarian, and cervical cancers. Onkologie 2011, 34:422-426.
169. 131I cytotoxicity in anaplastic thyroid cancer cells. Thyroid 2013, (Epub ahead of print).
170. Puppin C., D'Aurizio F., D'Elia A.V., Cesaratto L., Tell G., Russo D., Filetti S., Ferretti E., Tosi E., Mattei T., Pianta A., Pellizzari L., Damante G. Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology 2005, 146:3967-3974.
171. Puppin C., Passon N., Lavarone E., Di Loreto C., Frasca F., Vella V., Vigneri R., Damante G. Levels of histone acetylation in thyroid tumors. Biochem. Biophys. Res. Commun. 2011, 411:679-683.
172. Puxeddu E., Moretti S., Elisei R., Romei C., Pascucci R., Martinelli M., Marino C., Avenia N., Rossi E.D., Fadda G., Cavaliere A., Ribacchi R., Falorni A., Pontecorvi A., Pacini F., Pinchera A., Santeusanio F. BRAFV599E mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 2004, 89:2414-2420.
173. Puzianowska-Kuznicka M., Krystyniak A., Madej A., Cheng S.-Y., Nauman J. Functionally impaired TR mutants are present in thyroid papillary cancer. J. Clin. Endocrinol. Metab. 2002, 87:1120-1128.
174. Rabes H.M., Demidchik E.P., Sidorow J.D., Lengfelder E., Beimfohr C., Hoelzel D., Klugbauer S. Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin. Cancer Res. 2000, 6:1093-1103.
175. Reddi H.V., Madde P., Marlow L.A., Copland J.A., McIver B., Grebe S.K.G., Eberhardt N.L. Expression of the PAX8/PPARγ fusion protein is associated with decreased neovascularization in vivo: Impact on tumorigenesis and disease prognosis. Genes Cancer 2010, 1:480-492.
176. Reddi H.V., Madde P., Milosevic D., Hackbarth J.S., Algeciras-Schimnich A., McIver B., Grebe S.K.G., Eberhardt N.L. The putative PAX8/PPARγ fusion oncoprotein exhibits partial tumor suppressor activity through up-regulation of micro-RNA-122 and dominant-negative PPARγ activity. Genes Cancer 2011, 2:46-55.
177. Riesco-Eizaguirre G., Gutiérrez-Martínez P., García-Cabezas M.A., Nistal M., Santisteban P. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr. Relat. Cancer 2006, 13:257-269.
178. Riggs A.D. X inactivation, differentiation, and DNA methylation. Cytogenet. Cell Genet. 1975, 14:9-25.
179. Rocha A.S., Marques R., Bento I., Soares R., Magalhães J., de Castro I.V., Soares P. Thyroid hormone receptor beta mutations in the "hot-spot region" are rare events in thyroid carcinomas. J. Endocrinol. 2007, 192:83-86.
180. Rochefort P., Caillou B., Michiels F.M., Ledent C., Talbot M., Schlumberger M., Lavelle F., Monier R., Feunteun J. Thyroid pathologies in transgenic mice expressing a human activated Ras gene driven by a thyroglobulin promoter. Oncogene 1996, 12:111-118.
181. Saavedra H.I., Knauf J.A., Shirokawa J.M., Wang J., Ouyang B., Elisei R., Stambrook P.J., Fagin J.A. The RAS oncogene induces genomic instability in thyroid PCCL3 cells via the MAPK pathway. Oncogene 2000, 19:3948-3954.
182. Sabra M., Dominguez J., Grewal R., Larson S., Ghossein R., Tuttle R., Fagin J. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J. Clin. Endocrinol. Metab. 2013, 98:E829-36.
183. Sahin M., Allard B.L., Yates M., Powell J.G., Wang X.-L., Hay I.D., Zhao Y., Goellner J.R., Sebo T.J., Grebe S.K.G., Eberhardt N.L., McIver B. PPARγ staining as a surrogate for PAX8/PPARγ fusion oncogene expression in follicular neoplasms: clinicopathological correlation and histopathological diagnostic value. J. Clin. Endocrinol. Metab. 2005, 90:463-468.
184. Saji M., Narahara K., McCarty S.K., Vasko V.V., La Perle K.M., Porter K., Jarjoura D., Lu C., Cheng S.-Y., Ringel M.D. Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Oncogene 2011, 30:4307-4315.
185. Salvatore D., Barone M.V., Salvatore G., Melillo R.M., Chiappetta G., Mineo A., Fenzi G., Vecchio G., Fusco A., Santoro M. Tyrosines 1015 and 1062 are in vivo autophosphorylation sites in ret and ret-derived oncoproteins. J. Clin. Endocrinol. Metab. 2000, 85:3898-3907.
186. Santoro M., Melillo R., Grieco M., Berlingieri M., Vecchio G., Fusco A. The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Differ. 1993, 4:77-84.
187. Santoro M., Dathan N.A., Berlingieri M.T., Bongarzone I., Paulin C., Grieco M., Pierotti M.A., Vecchio G., Fusco A. Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene 1994, 9:509-516.
188. Santoro M., Chiappetta G., Cerrato A., Salvatore D., Zhang L., Manzo G., Picone A., Portella G., Santelli G., Vecchio G., Fusco A. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 1996, 12:1821-1826.
189. Santoro M., Papotti M., Chiappetta G., Garcia-Rostan G., Volante M., Johnson C., Camp R.L., Pentimalli F., Monaco C., Herrero A., Carcangiu M.L., Fusco A., Tallini G. RET activation and clinicopathologic features in poorly differentiated thyroid tumors. J. Clin. Endocrinol. Metab. 2002, 87:370-379.
190. Santoro M., Melillo R.M., Fusco A. RET/PTC activation in papillary thyroid carcinoma: European journal of endocrinology prize lecture. Eur. J. Endocrinol. 2006, 155:645-653.
191. Schagdarsurengin U., Gimm O., Hoang-Vu C., Dralle H., Pfeifer G.P., Dammann R. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma. Cancer Res. 2002, 62:3698-3701.
192. Schagdarsurengin U., Richter A.M., Wöhler C., Dammann R.H. Frequent epigenetic inactivation of RASSF10 in thyroid cancer. Epigenetics 2009, 4:571-576.
193. Schagdarsurengin U., Richter A.M., Hornung J., Lange C., Steinmann K., Dammann R.H. Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Mol. Cancer 2010, 9:264.
194. Schneider T.C., Abdulrahman R.M., Corssmit E.P., Morreau H., Smit J.W.A., Kapiteijn E. Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. Eur. J. Endocrinol. 2012, 167:643-650.
195. Shangary S., Ding K., Qiu S., Nikolovska-Coleska Z., Bauer J.A., Liu M., Wang G., Lu Y., McEachern D., Bernard D., Bradford C.R., Carey T.E., Wang S. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol. Cancer Ther. 2008, 7:1533-1542.
196. Shen Y., Ruan M., Luo Q., Yu Y., Lu H., Zhu R., Chen L. Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib. Thyroid 2012, 22:856-860.
197. Sherman E.J., Su Y.B., Lyall A., Schoder H., Fury M.G., Ghossein R.A., Haque S., Lisa D., Shaha A.R., Tuttle R.M., Pfister D.G. Evaluation of romidepsin for clinical activity and radioactive iodine reuptake in radioactive iodine-refractory thyroid carcinoma. Thyroid 2012, 23:593-599.
198. Smallridge R.C., Marlow L.A., Copland J.A. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr. Relat. Cancer 2009, 16:17-44.
199. Smallridge R.C., Ain K.B., Asa S.L., Bible K.C., Brierley J.D., Burman K.D., Kebebew E., Lee N.Y., Nikiforov Y.E., Rosenthal M.S., Shah M.H., Shaha A.R., Tuttle R.M. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. Thyroid 2012, 22:1104-1139.
200. Soares P., Fonseca E., Wynford-Thomas D., Sobrinho-Simões M. Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms?. J. Pathol. 1998, 185:71-78.
201. Sorrentino R., Libertini S., Pallante P.L., Troncone G., Palombini L., Bavetsias V., Spalletti-Cernia D., Laccetti P., Linardopoulos S., Chieffi P., Fusco A., Portella G. Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation. J. Clin. Endocrinol. Metab. 2005, 90:928-935.
202. Stegh A.H. Targeting the p53 signaling pathway in cancer therapy - the promises, challenges, and perils. Expert Opin. Ther. Targets 2012, 16:67-83.
203. Suarez H.G., du Villard J.A., Severino M., Caillou B., Schlumberger M., Tubiana M., Parmentier C., Monier R. Presence of mutations in all three ras genes in human thyroid tumors. Oncogene 1990, 5:565-570.
204. Suzuki H., Willingham M.C., Cheng S.-Y. Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. Thyroid 2002, 12:963-969.
205. Takano T., Miyauchi A., Yoshida H., Nakata Y., Kuma K., Amino N. Expression of TRbeta1 mRNAs with functionally impaired mutations is rare in thyroid papillary carcinoma. J. Clin. Endocrinol. Metab. 2003, 88:3447-3449.
206. Tallini G., Santoro M., Helie M., Carlomagno F., Salvatore G., Chiappetta G., Carcangiu M.L., Fusco A. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin. Cancer Res. 1998, 4:287-294.
207. Thomas G.A., Bunnell H., Cook H.A., Williams E.D., Nerovnya A., Cherstvoy E.D., Tronko N.D., Bogdanova T.I., Chiappetta G., Viglietto G., Pentimalli F., Salvatore G., Fusco A., Santoro M., Vecchio G. High prevalence of RET/PTC rearrangements in Ukrainian and Belarussian post-Chernobyl thyroid papillary carcinomas: a strong correlation between RET/PTC3 and the solid-follicular variant. J. Clin. Endocrinol. Metab. 1999, 84:4232-4238.
208. Thornton K., Kim G., Maher V.E., Chattopadhyay S., Tang S., Moon Y.J., Song P., Marathe A., Balakrishnan S., Zhu H., Garnett C., Liu Q., Booth B., Gehrke B., Dorsam R., Verbois L., Ghosh D., Wilson W., Duan J., Sarker H., Miksinski S.P., Skarupa L., Ibrahim A., Justice R., Murgo A., Pazdur R. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin. Cancer Res. 2012, 18:3722-3730.
209. Tuttle R.M., Ball D.W., Byrd D., Dilawari R.A., Doherty G.M., Duh Q.-Y., Ehya H., Farrar W.B., Haddad R.I., Kandeel F., Kloos R.T., Kopp P., Lamonica D.M., Loree T.R., Lydiatt W.M., McCaffrey J.C., Olson J.A., Parks L., Ridge J.A., Shah J.P., Sherman S.I., Sturgeon C., Waguespack S.G., Wang T.N., Wirth L.J. Thyroid carcinoma. J. Natl. Compr. Cancer Netw. 2010, 8:1228-1274.
210. Vassilev L.T., Vu B.T., Graves B., Carvajal D., Podlaski F., Filipovic Z., Kong N., Kammlott U., Lukacs C., Klein C., Fotouhi N., Liu E.A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303:844-848.
211. Venkataraman G.M., Yatin M., Marcinek R., Ain K.B. Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I- symporter gene methylation status. J. Clin. Endocrinol. Metab. 1999, 84:2449-2457.
212. Vitagliano D., Portella G., Troncone G., Francione A., Rossi C., Bruno A., Giorgini A., Coluzzi S., Nappi T.C., Rothstein J.L., Pasquinelli R., Chiappetta G., Terracciano D., Macchia V., Melillo R.M., Fusco A., Santoro M. Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas. Oncogene 2006, 25:5467-5474.
213. Vivaldi A., Miasaki F.Y., Ciampi R., Agate L., Collecchi P., Capodanno A., Pinchera A., Elisei R. Re-differentiation of thyroid carcinoma cell lines treated with 5-Aza-2'-deoxycytidine and retinoic acid. Mol. Cell. Endocrinol. 2009, 307:142-148.
214. Volante M., Rapa I., Gandhi M., Bussolati G., Giachino D., Papotti M., Nikiforov Y.E. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J. Clin. Endocrinol. Metab. 2009, 94:4735-4741.
215. Wan P.T.C., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
216. Wang J., Knauf J.A., Basu S., Puxeddu E., Kuroda H., Santoro M., Fusco A., Fagin J.A. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. Mol. Endocrinol. 2003, 17:1425-1436.
217. Wang Y., Hou P., Yu H., Wang W., Ji M., Zhao S., Yan S., Sun X., Liu D., Shi B., Zhu G., Condouris S., Xing M. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-Kinase/Akt pathway in thyroid tumors. J. Clin. Endocrinol. Metab. 2007, 92:2387-2390.
218. Wunderlich A., Fischer M., Schlosshauer T., Ramaswamy A., Greene B.H., Brendel C., Doll D., Bartsch D., Hoffmann S. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer. Cancer Sci. 2011, 102:762-768.
219. Xing M., Westra W.H., Tufano R.P., Cohen Y., Rosenbaum E., Rhoden K.J., Carson K.A., Vasko V., Larin A., Tallini G., Tolaney S., Holt E.H., Hui P., Umbricht C.B., Basaria S., Ewertz M., Tufaro A.P., Califano J.A., Ringel M.D., Zeiger M.A., Sidransky D., Ladenson P.W. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2005, 90:6373-6379.
220. Xing M., Alzahrani A.S., Carson K.A., Viola D., Elisei R., Bendlova B., Yip L., Mian C., Vianello F., Tuttle R.M., Robenshtok E., Fagin J.A., Puxeddu E., Fugazzola L., Czarniecka A., Jarzab B., O'Neill C.J., Sywak M.S., Lam A.K., Riesco-Eizaguirre G., Santisteban P., Nakayama H., Tufano R.P., Pai S.I., Zeiger M.A., Westra W.H., Clark D.P., Clifton-Bligh R., Sidransky D., Ladenson P.W., Sykorova V. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013, 309:1493-1501.
221. Yang Z., Zhou L., Wu L.-M., Lai M.-C., Xie H.-Y., Zhang F., Zheng S.-S. Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann. Surg. Oncol. 2011, 18:1243-1250.
222. Yeung S.-C.J., She M., Yang H., Pan J., Sun L., Chaplin D. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J. Clin. Endocrinol. Metab. 2007, 92:2902-2909.
223. Yin Y., Yuan H., Wang C., Pattabiraman N., Rao M., Pestell R.G., Glazer R.I. 3-Phosphoinositide-dependent protein kinase-1 activates the peroxisome proliferator-activated receptor-{gamma} and promotes adipocyte differentiation. Mol. Endocrinol. 2006, 20:268-278.
224. Yin Y., Yuan H., Zeng X., Kopelovich L., Glazer R.I. Inhibition of peroxisome proliferator-activated receptor γ increases estrogen receptor-dependent tumor specification. Cancer Res. 2009, 69:687-694.
225. Yoon H., He H., Nagy R., Davuluri R., Suster S., Schoenberg D., Pellegata N., de la Chapelle A. Identification of a novel noncoding RNA gene, NAMA, that is downregulated in papillary thyroid carcinoma with BRAF mutation and associated with growth arrest. Int. J. Cancer 2007, 121:767-775.
226. Zarnegar R., Brunaud L., Kanauchi H., Wong M., Fung M., Ginzinger D., Duh Q.-Y., Clark O.H. Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 2002, 132:984-999. (discussion 990).
227. Zhu Z., Gandhi M., Nikiforova M.N., Fischer A.H., Nikiforov Y.E. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of ras mutations. Am. J. Clin. Pathol. 2003, 120:71-77.
228. Zuo H., Gandhi M., Edreira M.M., Hochbaum D., Nimgaonkar V.L., Zhang P., Dipaola J., Evdokimova V., Altschuler D.L., Nikiforov Y.E. Downregulation of Rap1GAP through epigenetic silencing and loss of heterozygosity promotes invasion and progression of thyroid tumors. Cancer Res. 2010, 70:1389-1397.